Cost-Effectiveness of Venous Thromboembolism Prophylaxis During Neoadjuvant Chemotherapy for Ovarian Cancer.
Emma S RyanLaura J HavrileskyJulia Rose SalinaroBrittany A DavidsonPublished in: JCO oncology practice (2021)
Further confirmation of the true baseline VTE rate among women initiating neoadjuvant chemotherapy for ovarian cancer will determine whether prophylactic dose DOAC is a value-based strategy. Less costly VTE prophylaxis options such as generic DOACs (once available) and aspirin also warrant investigation.
Keyphrases
- neoadjuvant chemotherapy
- venous thromboembolism
- direct oral anticoagulants
- locally advanced
- lymph node
- sentinel lymph node
- low dose
- polycystic ovary syndrome
- cardiovascular events
- pregnancy outcomes
- antiplatelet therapy
- radiation therapy
- type diabetes
- atrial fibrillation
- early stage
- metabolic syndrome
- cervical cancer screening
- breast cancer risk
- adipose tissue
- percutaneous coronary intervention